Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity
- 1 January 2003
- journal article
- Published by Elsevier in Kidney International
- Vol. 63 (1) , 43-52
- https://doi.org/10.1046/j.1523-1755.2003.00707.x
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Angiotensin II blockade decreases TGF-β1 and matrix proteins in cyclosporine nephropathyKidney International, 1997
- Role of aldosterone in the remnant kidney model in the rat.Journal of Clinical Investigation, 1996
- COMBINED ANTAGONISM OF ENDOTHELIN A/B RECEPTORS LINKS ENDOTHELIN TO VASOCONSTRICTION WHEREAS ANGIOTENSIN II EFFECTS FIBROSISTransplantation, 1995
- A possible role for nitric oxide in modulating the functional cyclosporine toxicity by arginineKidney International, 1995
- Arginine feeding modifies cyclosporine nephrotoxicity in rats.Journal of Clinical Investigation, 1993
- Vasodilation to acetylcholine in primary and secondary forms of human hypertension.Hypertension, 1993
- Aldosterone reduces baroreceptor discharge in the dog.Hypertension, 1992
- Mineralocorticoid-induced increase in β-adrenergic receptors of cultured rat arterial smooth muscle cellsThe Journal of Steroid Biochemistry and Molecular Biology, 1989
- Effect of aldosterone on vascular angiotensin II receptors in the ratCanadian Journal of Physiology and Pharmacology, 1985